KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Non-Current Deferred Tax Liability (2016 - 2025)

Jazz Pharmaceuticals has reported Non-Current Deferred Tax Liability over the past 14 years, most recently at $1.1 billion for Q4 2025.

  • Quarterly results put Non-Current Deferred Tax Liability at $1.1 billion for Q4 2025, down 10.38% from a year ago — trailing twelve months through Dec 2025 was $1.1 billion (down 10.38% YoY), and the annual figure for FY2025 was $1.1 billion, down 10.38%.
  • Non-Current Deferred Tax Liability for Q4 2025 was $1.1 billion at Jazz Pharmaceuticals, up from $629.0 million in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for JAZZ hit a ceiling of $1.4 billion in Q2 2021 and a floor of $109.9 million in Q1 2021.
  • Median Non-Current Deferred Tax Liability over the past 5 years was $921.5 million (2023), compared with a mean of $925.1 million.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: tumbled 33.42% in 2021 and later skyrocketed 1011.84% in 2022.
  • Jazz Pharmaceuticals' Non-Current Deferred Tax Liability stood at $1.3 billion in 2021, then dropped by 27.39% to $944.3 million in 2022, then fell by 10.23% to $847.7 million in 2023, then skyrocketed by 40.24% to $1.2 billion in 2024, then decreased by 10.38% to $1.1 billion in 2025.
  • The last three reported values for Non-Current Deferred Tax Liability were $1.1 billion (Q4 2025), $629.0 million (Q3 2025), and $682.1 million (Q2 2025) per Business Quant data.